Table 1. Characteristics of biological therapies currently approved or under development for the treatment of severe asthma. DrugTargetMechanism of actionRoute of administrationStatusEndotype Omalizumab IgE Binds circulating IgE and prevents the interaction with high-affinity IgE receptor FcεRI Subcutaneous...
Minimizing the size of dupilumab to scFv to increase its non-invasive permeability, which is determined by the size of the material, may allow it to be used as a non-invasive route of administration, such as a nasal spray rather than an injection. Recent single-cell RNA sequencing studies ...
when added to guideline-based inhaled antiasthma treatment.45 This 6-month study, involv- ing 219 adult asthmatic subjects not adequately controlled by inhaled corticosteroids (ICS), evaluated the therapeutic activity of lebrikizumab given by the subcutaneous route every month at a dose of 250 mg...